Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy) : a phase 3, randomised, controlled, open-label trial
Copyright © 2022 Elsevier Ltd. All rights reserved..
BACKGROUND: The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support.
METHODS: DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg). Adult patients (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and illness of any duration were eligible if they had clinical evidence of hypoxaemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzymes, severe chronic kidney disease, any contraindication to one of the studied treatments or their use in the 29 days before random assignment, or use of ribavirin, as well as pregnancy or breastfeeding. Participants were randomly assigned (1:1:1:1:1) to receive standard of care alone or in combination with remdesivir, lopinavir-ritonavir, lopinavir-ritonavir and interferon beta-1a, or hydroxychloroquine. Randomisation used computer-generated blocks of various sizes; it was stratified on severity of disease at inclusion and on European administrative region. Remdesivir was administered as 200 mg intravenous infusion on day 1, followed by once daily, 1-h infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. The primary outcome was the clinical status at day 15 measured by the WHO seven-point ordinal scale, assessed in the intention-to-treat population. Safety was assessed in the modified intention-to-treat population and was one of the secondary outcomes. This trial is registered with the European Clinical Trials Database, EudraCT2020-000936-23, and ClinicalTrials.gov, NCT04315948.
FINDINGS: Between March 22, 2020, and Jan 21, 2021, 857 participants were enrolled and randomly assigned to remdesivir plus standard of care (n=429) or standard of care only (n=428). 15 participants were excluded from analysis in the remdesivir group, and ten in the control group. At day 15, the distribution of the WHO ordinal scale was: (1) not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]). The difference between treatment groups was not significant (odds ratio 0·98 [95% CI 0·77-1·25]; p=0·85). There was no significant difference in the occurrence of serious adverse events between treatment groups (remdesivir, 135 [33%] of 406 vs control, 130 [31%] of 418; p=0·48). Three deaths (acute respiratory distress syndrome, bacterial infection, and hepatorenal syndrome) were considered related to remdesivir by the investigators, but only one by the sponsor's safety team (hepatorenal syndrome).
INTERPRETATION: No clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support.
FUNDING: European Union Commission, French Ministry of Health, Domaine d'intérêt majeur One Health Île-de-France, REACTing, Fonds Erasme-COVID-Université Libre de Bruxelles, Belgian Health Care Knowledge Centre, Austrian Group Medical Tumor, European Regional Development Fund, Portugal Ministry of Health, Portugal Agency for Clinical Research and Biomedical Innovation.
TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
| Errataetall: |
CommentIn: Lancet Infect Dis. 2021 Sep 14;:null. - PMID 34534513 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 22(2022), 2 vom: 16. Feb., Seite 209-221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ader, Florence [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.02.2022 Date Revised 21.12.2022 published: Print-Electronic ClinicalTrials.gov: NCT04315948 CommentIn: Lancet Infect Dis. 2021 Sep 14;:null. - PMID 34534513 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(21)00485-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330764756 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330764756 | ||
| 003 | DE-627 | ||
| 005 | 20231225212003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(21)00485-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330764756 | ||
| 035 | |a (NLM)34534511 | ||
| 035 | |a (PII)S1473-3099(21)00485-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ader, Florence |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy) |b a phase 3, randomised, controlled, open-label trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04315948 | ||
| 500 | |a CommentIn: Lancet Infect Dis. 2021 Sep 14;:null. - PMID 34534513 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support | ||
| 520 | |a METHODS: DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg). Adult patients (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and illness of any duration were eligible if they had clinical evidence of hypoxaemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzymes, severe chronic kidney disease, any contraindication to one of the studied treatments or their use in the 29 days before random assignment, or use of ribavirin, as well as pregnancy or breastfeeding. Participants were randomly assigned (1:1:1:1:1) to receive standard of care alone or in combination with remdesivir, lopinavir-ritonavir, lopinavir-ritonavir and interferon beta-1a, or hydroxychloroquine. Randomisation used computer-generated blocks of various sizes; it was stratified on severity of disease at inclusion and on European administrative region. Remdesivir was administered as 200 mg intravenous infusion on day 1, followed by once daily, 1-h infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. The primary outcome was the clinical status at day 15 measured by the WHO seven-point ordinal scale, assessed in the intention-to-treat population. Safety was assessed in the modified intention-to-treat population and was one of the secondary outcomes. This trial is registered with the European Clinical Trials Database, EudraCT2020-000936-23, and ClinicalTrials.gov, NCT04315948 | ||
| 520 | |a FINDINGS: Between March 22, 2020, and Jan 21, 2021, 857 participants were enrolled and randomly assigned to remdesivir plus standard of care (n=429) or standard of care only (n=428). 15 participants were excluded from analysis in the remdesivir group, and ten in the control group. At day 15, the distribution of the WHO ordinal scale was: (1) not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]). The difference between treatment groups was not significant (odds ratio 0·98 [95% CI 0·77-1·25]; p=0·85). There was no significant difference in the occurrence of serious adverse events between treatment groups (remdesivir, 135 [33%] of 406 vs control, 130 [31%] of 418; p=0·48). Three deaths (acute respiratory distress syndrome, bacterial infection, and hepatorenal syndrome) were considered related to remdesivir by the investigators, but only one by the sponsor's safety team (hepatorenal syndrome) | ||
| 520 | |a INTERPRETATION: No clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support | ||
| 520 | |a FUNDING: European Union Commission, French Ministry of Health, Domaine d'intérêt majeur One Health Île-de-France, REACTing, Fonds Erasme-COVID-Université Libre de Bruxelles, Belgian Health Care Knowledge Centre, Austrian Group Medical Tumor, European Regional Development Fund, Portugal Ministry of Health, Portugal Agency for Clinical Research and Biomedical Innovation | ||
| 520 | |a TRANSLATION: For the French translation of the abstract see Supplementary Materials section | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Bouscambert-Duchamp, Maude |e verfasserin |4 aut | |
| 700 | 1 | |a Hites, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Peiffer-Smadja, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Poissy, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Belhadi, Drifa |e verfasserin |4 aut | |
| 700 | 1 | |a Diallo, Alpha |e verfasserin |4 aut | |
| 700 | 1 | |a Lê, Minh-Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Peytavin, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Staub, Thérèse |e verfasserin |4 aut | |
| 700 | 1 | |a Greil, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Guedj, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, Jose-Artur |e verfasserin |4 aut | |
| 700 | 1 | |a Costagliola, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e verfasserin |4 aut | |
| 700 | 1 | |a Burdet, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Mentré, France |e verfasserin |4 aut | |
| 700 | 0 | |a DisCoVeRy Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Egle, Alexander |e investigator |4 oth | |
| 700 | 1 | |a Greil, Richard |e investigator |4 oth | |
| 700 | 1 | |a Joannidis, Michael |e investigator |4 oth | |
| 700 | 1 | |a Lamprecht, Bernd |e investigator |4 oth | |
| 700 | 1 | |a Altdorfer, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Belkhir, Leila |e investigator |4 oth | |
| 700 | 1 | |a Fraipont, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Hites, Maya |e investigator |4 oth | |
| 700 | 1 | |a Verschelden, Gil |e investigator |4 oth | |
| 700 | 1 | |a Aboab, Jérôme |e investigator |4 oth | |
| 700 | 1 | |a Ader, Florence |e investigator |4 oth | |
| 700 | 1 | |a Ait-Oufella, Hafid |e investigator |4 oth | |
| 700 | 1 | |a Andrejak, Claire |e investigator |4 oth | |
| 700 | 1 | |a Andreu, Pascal |e investigator |4 oth | |
| 700 | 1 | |a Argaud, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Bani-Sadr, Firouzé |e investigator |4 oth | |
| 700 | 1 | |a Benezit, François |e investigator |4 oth | |
| 700 | 1 | |a Blot, Mathieu |e investigator |4 oth | |
| 700 | 1 | |a Botelho-Nevers, Elisabeth |e investigator |4 oth | |
| 700 | 1 | |a Bouadma, Lila |e investigator |4 oth | |
| 700 | 1 | |a Bouchaud, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Bougon, David |e investigator |4 oth | |
| 700 | 1 | |a Bouiller, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Bounes-Vardon, Fanny |e investigator |4 oth | |
| 700 | 1 | |a Boutoille, David |e investigator |4 oth | |
| 700 | 1 | |a Boyer, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Bruel, Cédric |e investigator |4 oth | |
| 700 | 1 | |a Cabié, André |e investigator |4 oth | |
| 700 | 1 | |a Canet, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Cazanave, Charles |e investigator |4 oth | |
| 700 | 1 | |a Chabartier, Cyrille |e investigator |4 oth | |
| 700 | 1 | |a Chirouze, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Clere-Jehl, Raphaël |e investigator |4 oth | |
| 700 | 1 | |a Courjon, Johan |e investigator |4 oth | |
| 700 | 1 | |a Crockett, Flora |e investigator |4 oth | |
| 700 | 1 | |a Danion, François |e investigator |4 oth | |
| 700 | 1 | |a Delbove, Agathe |e investigator |4 oth | |
| 700 | 1 | |a Dellamonica, Jean |e investigator |4 oth | |
| 700 | 1 | |a Djossou, Félix |e investigator |4 oth | |
| 700 | 1 | |a Dubost, Clément |e investigator |4 oth | |
| 700 | 1 | |a Duvignaud, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Epaulard, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Epelboin, Loïc |e investigator |4 oth | |
| 700 | 1 | |a Fartoukh, Murielle |e investigator |4 oth | |
| 700 | 1 | |a Faure, Karine |e investigator |4 oth | |
| 700 | 1 | |a Faure, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Ferry, Tristan |e investigator |4 oth | |
| 700 | 1 | |a Ficko, Cécile |e investigator |4 oth | |
| 700 | 1 | |a Figueiredo, Samy |e investigator |4 oth | |
| 700 | 1 | |a Gaborit, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Gaci, Rostane |e investigator |4 oth | |
| 700 | 1 | |a Gagneux-Brunon, Amandine |e investigator |4 oth | |
| 700 | 1 | |a Gallien, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Garot, Denis |e investigator |4 oth | |
| 700 | 1 | |a Geri, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Gibot, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Goehringer, François |e investigator |4 oth | |
| 700 | 1 | |a Gousseff, Marie |e investigator |4 oth | |
| 700 | 1 | |a Gruson, Didier |e investigator |4 oth | |
| 700 | 1 | |a Hansmann, Yves |e investigator |4 oth | |
| 700 | 1 | |a Hinschberger, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Jaureguiberry, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Jeanmichel, Vanessa |e investigator |4 oth | |
| 700 | 1 | |a Kerneis, Solen |e investigator |4 oth | |
| 700 | 1 | |a Kimmoun, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Klouche, Kada |e investigator |4 oth | |
| 700 | 1 | |a Lachâtre, Marie |e investigator |4 oth | |
| 700 | 1 | |a Lacombe, Karine |e investigator |4 oth | |
| 700 | 1 | |a Laine, Fabrice |e investigator |4 oth | |
| 700 | 1 | |a Lanoix, Jean-Philippe |e investigator |4 oth | |
| 700 | 1 | |a Launay, Odile |e investigator |4 oth | |
| 700 | 1 | |a Laviolle, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Le Moing, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Le Pavec, Jérôme |e investigator |4 oth | |
| 700 | 1 | |a Le Tulzo, Yves |e investigator |4 oth | |
| 700 | 1 | |a Le Turnier, Paul |e investigator |4 oth | |
| 700 | 1 | |a Lebeaux, David |e investigator |4 oth | |
| 700 | 1 | |a Lefevre, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Leroy, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Lescure, François-Xavier |e investigator |4 oth | |
| 700 | 1 | |a Lessire, Henry |e investigator |4 oth | |
| 700 | 1 | |a Leveau, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Loubet, Paul |e investigator |4 oth | |
| 700 | 1 | |a Makinson, Alain |e investigator |4 oth | |
| 700 | 1 | |a Malvy, Denis |e investigator |4 oth | |
| 700 | 1 | |a Marquette, Charles-Hugo |e investigator |4 oth | |
| 700 | 1 | |a Martin-Blondel, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Martinot, Martin |e investigator |4 oth | |
| 700 | 1 | |a Mayaux, Julien |e investigator |4 oth | |
| 700 | 1 | |a Mekontso-Dessap, Armand |e investigator |4 oth | |
| 700 | 1 | |a Meziani, Ferhat |e investigator |4 oth | |
| 700 | 1 | |a Mira, Jean-Paul |e investigator |4 oth | |
| 700 | 1 | |a Molina, Jean-Michel |e investigator |4 oth | |
| 700 | 1 | |a Monnet, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Mootien, Joy |e investigator |4 oth | |
| 700 | 1 | |a Mourvillier, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Murris-Espin, Marlène |e investigator |4 oth | |
| 700 | 1 | |a Navellou, Jean-Christophe |e investigator |4 oth | |
| 700 | 1 | |a Nseir, Saad |e investigator |4 oth | |
| 700 | 1 | |a Oulehri, Walid |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 22(2022), 2 vom: 16. Feb., Seite 209-221 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:2 |g day:16 |g month:02 |g pages:209-221 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(21)00485-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 2 |b 16 |c 02 |h 209-221 | ||